Appendix A1.
N cases (%) | N controls (%) | Crude OR | 95% CI | Adj. OR | 95% CI | |
---|---|---|---|---|---|---|
No autoimmune disease | 1.00 | --- | 1.00 | --- | ||
Any autoimmune disease | 19 (0.9) | 134 (1.3) | 0.68 | 0.42–1.12 | 0.70 | 0.43–1.15 |
IBD | 12 (0.6) | 61 (0.6) | 1.01 | 0.54–1.89 | 1.07 | 0.57–2.00 |
Rheumatic disease | 7(0.3) | 74 (0.7) | 0.41 | 0.18–0.94 | 0.41 | 0.18–0.94 |
No AI medication purchases | 1.00 | --- | 1.00 | --- | ||
Any AI medication purchase | 169 (8.3) | 888 (8.8) | 0.95 | 0.80–1.13 | 0.96 | 0.80–1.14 |
IBD medication | 13 (0.6) | 65 (0.6) | 1.01 | 0.56–1.84 | 1.07 | 0.59–1.95 |
Systemic corticosteroids | 21(1.0) | 107 (1.1) | 0.91 | 0.56–1.49 | 0.93 | 0.57–1.52 |
Immunosuppressants | 3 (0.1) | 13 (0.1) | 0.83 | 0.19–3.72 | 0.90 | 0.20–4.06 |
Anti-inflammatory and -rheumatic products | 141 (6.9) | 761 (7.5) | 0.93 | 0.77–1.13 | 0.93 | 0.77–1.13 |
Stratified, unadjusted analysis
Stratified analysis adjusted for maternal age (categorized), parity and smoking status.